Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Obesity drug supply delay not unusual says Novo Nordisk CEO
05:40am, Thursday, 04'th Aug 2022
Novo Nordisk sought to soothe concerns about supplies of its new obesity drug Wegovy on Thursday, saying there was nothing unusual about a slight delay in its availability.
Novo Nordisk A/S (NVO) CEO Lars Fruergaard Joergensen on Q2 2022 Results - Earnings Call Transcript
08:50pm, Wednesday, 03'rd Aug 2022
Novo Nordisk A/S (NVO) Q2 2022 Earnings Conference Call August 3, 2022 1:30 PM ET Company Participants Lars Fruergaard Joergensen - Chief Executive Officer Camilla Sylvest - Executive Vice President &
AMD, SolarEdge Technologies And Some Other Big Stocks Moving Lower On Wednesday
03:33pm, Wednesday, 03'rd Aug 2022 Benzinga
Rocky Brands, Inc. (NASDAQ: RCKY) dipped 21.6% to $26.62 after the company reported worse-than-expected Q2 EPS results.
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) dropped 21.3% to $64
Drug, Biotech Stocks' Q2 Earnings on Aug 4: LLY, AMGN & More
01:48pm, Wednesday, 03'rd Aug 2022 Zacks Investment Research
Let us look at four large drug and biotech companies, AMGN, VRTX, LLY, NVO, which are gearing up for their earnings release.
Novo Nordisk's Obesity Sales Nearly Doubled, But That Wasn't Enough For NVO Stock
12:23pm, Wednesday, 03'rd Aug 2022
Danish drugmaker Novo Nordisk missed quarterly views Wednesday, but raised its full-year outlook. Still, NVO stock tumbled.
Novo Nordisk raises 2022 outlook after strong first half
10:39am, Wednesday, 03'rd Aug 2022
Danish drugmaker Novo Nordisk on Wednesday lifted its sales and operating profit outlook for the year on the back of strong first-half earnings.
Novo Nordisk (NVO) to Report Q2 Earnings: What's in the Cards?
04:07pm, Monday, 01'st Aug 2022 Zacks Investment Research
Novo Nordisk's (NVO) top line is likely to have been driven by sales of its Diabetes and Obesity Care products in the second quarter of 2022.
Alnylam's Strategy Is Getting Bigger. Time to Buy?
09:31am, Saturday, 30'th Jul 2022 The Motley Fool
After decades of developing rare-disease drugs, this RNA pioneer will aim for much larger audiences.
2 High-Yield Dividend Aristocrats Potentially Set To Soar And 10 You Should Ignore
01:15pm, Saturday, 23'rd Jul 2022 Seeking Alpha
Dividends are an essential part of achieving life-changing wealth in the stock market. Click here for 2 high-yield dividend aristocrats potentially set to soar.
2 Pharma Giants With Momentum That Could Carry Through 2030
03:30pm, Friday, 22'nd Jul 2022 The Motley Fool
An obese population could drive competition toward a valuable market.
The Zacks Analyst Blog Highlights AMN Healthcare, Boeing, Clorox, Novo Nordisk and Costco Wholesale
10:40am, Tuesday, 19'th Jul 2022 Zacks Investment Research
AMN Healthcare, Boeing, Clorox, Novo Nordisk and Costco Wholesale have been included in this Analyst Blog.
Beat the Market Like Zacks: AMN Healthcare, Boeing, Clorox, Home Depot in Focus
11:39am, Monday, 18'th Jul 2022 Zacks Investment Research
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our accomplishments from last week.
Beat the Market Like Zacks: AMN Healthcare, Boeing, Clorox, Home Depot in Focus
09:18am, Monday, 18'th Jul 2022
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our accomplishments from last week.
Marinus (MRNS) to Sell Rare Disease PRV to Novo Nordisk
03:43pm, Friday, 15'th Jul 2022 Zacks Investment Research
Marinus Pharmaceuticals (MRNS) agrees to sell its Rare Pediatric Disease Priority Review Voicer (RPV) to Novo Nordisk for $110 million.
Marinus to sell rare-disease voucher to Novo Nordisk for $110 million
09:11am, Thursday, 14'th Jul 2022
Shares of Marinus Pharmaceuticals Inc. MRNS, +4.13% gained 7.9% in premarket trading on Thursday after the company said it plans to sell its Rare Pediatric Disease Priority Review Voucher for $110 mil
